BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sands Capital Management | 159,247 | $55,201,000 | 0.19% |
| S&CO INC | 6,520 | $2,260,000 | 0.19% |
| XTX Topco Ltd | 1,296 | $449,000 | 0.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 3,718 | $1,289,000 | 0.18% |
| Cinctive Capital Management LP | 12,337 | $4,276,000 | 0.18% |
| NAPLES GLOBAL ADVISORS, LLC | 3,950 | $1,369,000 | 0.18% |
| Lifeworks Advisors, LLC | 800 | $277,000 | 0.18% |
| Zions Bancorporation, N.A. | 4,988 | $1,729,000 | 0.17% |
| Paradigm Financial Partners, LLC | 1,555 | $573,000 | 0.17% |
| Spouting Rock Asset Management, LLC | 762 | $264,000 | 0.17% |
| Dougherty Wealth Advisers LLC | 259 | $90,000 | 0.17% |
| SVB WEALTH LLC | 31,496 | $10,918,000 | 0.17% |
| Engineers Gate Manager LP | 13,157 | $4,561,000 | 0.17% |
| Donoghue Forlines LLC | 1,833 | $635,000 | 0.17% |
| First City Capital Management, Inc. | 775 | $269,000 | 0.17% |
| Qtron Investments LLC | 2,143 | $743,000 | 0.16% |
| Radnor Capital Management, LLC | 1,688 | $585,000 | 0.16% |
| SEEYOND | 4,018 | $1,392,000 | 0.16% |
| ClariVest Asset Management LLC | 10,290 | $3,567,000 | 0.16% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 27,408 | $9,501,000 | 0.15% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.